Cellect Biotechnology Ltd., of Tel Aviv, Israel, said the FDA has provided the pre-investigational new drug (IND) meeting minutes supporting an IND submission for its Apograft. The submission review included the manufacturing (CMC) aspects, the preclinical data and the scope and design of the future clinical program.